Josh    Disbrow, Chief Executive Officer of Aytu    BioScience, stated, "These latest research findings continue to    add to the clinical and scientific evidence supporting use of    our MiOXSYS System, which we've already demonstrated to    be a useful clinical tool for assessing oxidative stress levels    in semen as it relates to male infertility. These seven    presentations at ESHRE, presented by leading andrologists and    urologists from infertility centers around the world,    demonstrate the broad interest and significant potential for    clinical use of the MiOXSYS System as an aid in the    diagnosis of male factor infertility."  
    The poster presentations were as follows:  
    Title: ORP: A Reliable and Reproducible Method of    Evaluating Oxidative Stress - A Multicenter Study    Poster Number: G17-0526    Session: 36    Presenter: Ashok    Agarwal, Ph.D., Director of the Andrology Center    and Director of the American Center for Reproductive Medicine    at the Glickman Urological & Kidney Institute, Cleveland    Clinic, Cleveland, OH    Conclusion: Although other semen parameters showed    significant differences between the two centers, sORP remained    consistent in both data sets individually or in combined data.    This proves its reproducibility and reliability. sORP is a    measure of semen quality which adds more weight to semen    testing in identifying fertile from infertile semen samples.  
    Title: Effect of Seminal ORP Value on Embryo Quality and    Clinical Pregnancy Rate    Poster Number: G17-1357    Session: Andrology    Presenter: B. Balaban, VKF American Hospital  Assisted    Reproduction Unit stanbul, Turkey     Conclusion: These findings may have important diagnostic    and prognostic implications for couples experiencing male    factor infertility and undergoing assisted reproductive    technique (ART). Further studies are warranted to explore the    mechanism of increased ORP in a subset of couples (male factor,    no female factor) undergoing ART to corroborate the    significance of these findings.  
    Title: Oxidation-Reduction Potential and Sperm DNA    Fragmentation Levels in Sperm Morphologic Anomalies    Poster Number: G17-0075    Session: 36    Presenter: A. Majzoub, Urology Department  Hamad    Medical Corporation, Doha, Qatar;    Conclusion: Results were obtained from semen samples of    patients presenting with primary or secondary infertility and    hence were not compared with a control group or with men of    proven fertility. Studying the correlation between sperm    morphology indices and advanced sperm function tests is    important as this would help in resting the controversy    surrounding its clinical implication on fertility potential. It    may also provide insights for developing novel sperm selection    techniques that can be utilized during assisted reproduction.  
    Title: Oxidation-Reduction Potential: A Valuable Tool    for Male Fertility Evaluation.    Poster Number: G17-0182    Session: 4    Presenter: A. Majzoub, Urology Department  Hamad    Medical Corporation, Doha, Qatar;    Conclusion: ORP measurement with the MiOXSYS    System is a simple, quick and user friendly method that can    reliably measure OS in biologic samples. The significant    correlation between ORP and total motile sperm count allows its    use as a predictor of fertility potential.  
    Title: High Levels of Seminal Oxidation-Reduction    Potential (ORP) in Infertile Men with Clinical Varicocele    Poster Number: G17-0995    Session: Andrology    Presenter: R. Saleh, Director, Ajyal Hospital, Sohag,    Egypt    Conclusion: These findings may have important diagnostic    and therapeutic implications. Further studies are warranted to    explore the mechanism of increased ORP in a subset of infertile    men with clinical varicocele. In addition, future studies may    help determine those patients who would benefit from    antioxidant therapy and/or surgical repair of varicocele.  
    Title: Oxidation-Reduction Potential Can Help    Distinguish Semen Samples Under Oxidative Stress    Poster Number: G17-0954    Session: Andrology    Presenter: S. Roychoudhury, Assam University, Silchar,    India    Conclusion: Measuring sORP can help a clinician    understand if comparatively one semen sample is under higher    state of oxidative stress than another.  
    Title: Correlation of Sperm DNA fragmentation and    Seminal Oxidation Reduction Potential in Infertile Men    Poster Number: G17-0055    Session: Andrology    Presenter: H. Elbardisi, Urology Department  Hamad    Medical Corporation, Doha, Qatar;    Conclusion: Sperm DNA fragmentation and seminal    oxidation reduction potential should be included in assessment    of male infertility. Using ORP testing can help in detecting    the target patients for antioxidant therapy.  
    Selection of the abstracts for publication in the press program    does not imply endorsement of the MiOXSYS System by    ESHRE.  
    About Aytu BioScience, Inc.  
    Aytu BioScience is a commercial-stage specialty pharmaceutical    company focused on global commercialization of novel products    in the field of urology, with a focus on products addressing    vitality, sexual wellness, and reproductive health. The company    currently markets two prescription products in the U.S.:    Natesto, the first and only FDA-approved nasal formulation of    testosterone for men with hypogonadism (low testosterone, or    "Low T") and ProstaScint (capromab pendetide), the only    FDA-approved imaging agent specific to prostate specific    membrane antigen (PSMA) for prostate cancer detection and    staging. Additionally, Aytu is developing MiOXSYS, a novel,    rapid semen analysis system with the potential to become a    standard of care for the diagnosis and management of male    infertility caused by oxidative stress. MiOXSYS is    commercialized outside the U.S. where it is a CE Marked, Health    Canada cleared product, and Aytu is planning U.S.-based    clinical trials in pursuit of 510k medical device clearance by    the FDA. Aytu's strategy is to continue building its portfolio    of revenue-generating products, leveraging its focused    commercial team and expertise to build leading brands within    growing markets. For more information visit aytubio.com. Aytu    also now owns wholly-owned subsidiary Aytu Women's Health    (formerly Nuelle, Inc.), a personal health and wellness company    focused on women's sexual wellbeing and intimacy that markets    Fiera, a personal care device for women that is scientifically    proven to enhance physical arousal and sexual desire. Fiera is    a consumer device and is not intended to treat, mitigate, or    cure any disease or medical condition. For more information    about the Fiera personal care device visit fiera.com.  
    Forward Looking Statement  
    This press release includes forward-looking statements within    the meaning of Section 27A of the Securities Act of 1933, as    amended, and Section 21E of the Securities Exchange Act of    1934, or the Exchange Act. All statements other than statements    of historical facts contained in this presentation, including    statements regarding our anticipated future clinical and    regulatory events, future financial position, business strategy    and plans and objectives of management for future operations,    are forward-looking statements. Forward looking statements are    generally written in the future tense and/or are preceded by    words such as "may," "will," "should," "forecast," "could,"    "expect," "suggest," "believe," "estimate," "continue,"    "anticipate," "intend," "plan," or similar words, or the    negatives of such terms or other variations on such terms or    comparable terminology. These statements are just predictions    and are subject to risks and uncertainties that could cause the    actual events or results to differ materially. These risks and    uncertainties include, among others: risks relating to gaining    market acceptance of our products, obtaining reimbursement by    third-party payors, the potential future commercialization of    our product candidates, the anticipated start dates, durations    and completion dates, as well as the potential future results,    of our ongoing and future clinical trials, the anticipated    designs of our future clinical trials, anticipated future    regulatory submissions and events, our anticipated future cash    position and future events under our current and potential    future collaborations. We also refer you to the risks described    in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s    Annual Report on Form 10-K and in the other reports and    documents we file with the Securities and Exchange Commission    from time to time.  
    Investor contact:  
    Amato and Partners, LLC  
    Investor Relations Counsel  
    admin@amatoandpartners.com  
    To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aytu-bioscience-presents-clinical-findings-for-its-mioxsys-system-at-33rd-annual-meeting-of-the-european-society-of-human-reproduction-and-embryology-300482828.html  
    SOURCE Aytu BioScience, Inc.  
Home
Continued here:
Aytu BioScience Presents Clinical Findings for its MiOXSYS System at 33rd Annual Meeting of the European Society ... - PR Newswire (press release)